Trial registration number
|
JPRN-jRCTs071200048 |
Full text link
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
https://jrct.niph.go.jp/latest-detail/jRCTs071200048
|
First author
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Takeshi Tanaka
|
Contact
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
ttakeshi@nagasaki-u.ac.jp
|
Registration date
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
2020-10-29
|
Recruitment status
Last imported at : Oct. 21, 2021, 10 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Not recruiting
|
Study design
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
RCT
|
Allocation
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Randomized
|
Design
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Parallel
|
Masking
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Open label
|
Center
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
unclear
|
Study aim
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Treatment
|
Inclusion criteria
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1: 20 years old or older at the time of informed consent2:gender:both3:inpatient and outpatient4:Confirmed infection with SARS-Cov-25:Patient with mild or moderate patients with COVID-19 according to Clinical Management of Patients with COVID-19, a guide for front-line healthcare workers version3.06:can provide signed informed consent
|
Exclusion criteria
Last imported at : July 16, 2021, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1: asymptomatic or severe SARS-CoV-2 positive patients2: Known history of porphyria, hemochromatosis or Viral hepatitis3: Patients with serious renal, hepatic, or cardiac disease etc.4: Patients who have lung disease that potentially become severe COVID-19 and who have poorly controlled hypertension and diabetes mellitus5: Pregnant or possibly pregnant women, lactating women, and women who desire to become pregnant during the study period 6:Patients participating in other clinical (human) trials7:Patients who have photosensitivity8:Patients who have alcoholism or severe mental disorder9:Demonstrate hypersensitivity to 5-aminolevulinic phosphoric acid or sodium ferrous citrate10:Patients who received COVID-19 approved drugs, excluding steroids, after the onset of COVID-19 symptoms11:Patients who received off-label use drugs available in Japan, excluding steroids, listed in the COVID-19 clinical guide after the onset of COVID-19 symptoms (including cases where they are used for purposes other than the treatment of COVID-19)12:Other patients judged to be inappropriate for the study by the attending physician
|
Number of arms
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
2
|
Funding
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Izumikawa Koichi
|
Inclusion age min
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
20
|
Inclusion age max
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
100
|
Countries
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Japan
|
Type of patients
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Mild/moderate disease at enrollment
|
Severity scale
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
2: Mild/moderate disease at enrollment
|
Total sample size
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
50
|
primary outcome
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Changes in SARS-CoV-2 viral load; changes in clinical symptom and safety of 5-ALA/SFC
|
Notes
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
|
Phase
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Phase 2
|
Arms
Last imported at : Nov. 6, 2020, 11:45 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
[{"arm_notes": "", "treatment_id": 4, "treatment_name": "5-ala/sfc", "treatment_type": "Nutrition", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|